An announcement from EVEREST MED (01952) discloses that the company's board has been informed by Mr. Fu Wei, a non-executive director, honorary chairman, and a principal shareholder, of a recent share acquisition. On June 3, 2026, C-Bridge Capital, acting as a major shareholder, purchased 690,000 ordinary shares of the company on the open market.

The total consideration for this transaction was approximately HK$20 million, resulting in an average price of about HK$28.93 per share. According to statements from Mr. Fu Wei and C-Bridge Capital, this on-market acquisition was executed based on their firm confidence in the company's future prospects and long-term development.

Subject to compliance with all applicable laws and regulations, Mr. Fu Wei and C-Bridge Capital have indicated they do not rule out the possibility of further increasing their shareholding in the company at an appropriate time in the future.